A. Dutt et al. / Journal of Molecular Structure 928 (2009) 138–143
139
evaporated. The residue obtained was diluted with water and
washed with diethyl ether. The aqueous layer was cooled in ice
and neutralised by 2 M HCl and extracted with ethyl acetate. The
solvent was evaporated in vacuo to give a white solid.
Yield: 0.87 g (90.0%). Anal. Calcd. for C28H44N4O7 (548.664): C,
61.29; H, 8.08; N, 10.21%. Found: C, 61.42; H, 8.25; N, 10.38%.
O
H
O
O
H
O
H
N
H
N
H
N
H
OH
N
H
2.1.3. H2N-Ile(1)-Aib(2)-Leu(3)-m-ABA(4)-CO2H(Peptide I)
Fig. 1. Schematic representation of peptide I.
To 0.6 g (1.09 mmol) of 2, 2 ml of TFA was added at 0 °C. The
reaction mixture was then stirred at room temperature and the
progress of deprotection of Boc-group was determined by thin
layer chromatography (TLC). After 6 h TFA was removed com-
pletely under vacuo and the residue was taken in water, washed
with diethyl ether. The aqueous part was then dried under vacuo
to yield I as a white solid. Purification was done using silica-gel
as the stationary phase and chloroform–methanol mixture as the
eluent. Single crystals of the compound were grown from water–
ethanol mixture by slow evaporation.
2. Experimental
2.1. Synthesis of peptides
The protected tetrapeptide was synthesized by conventional
solution phase methods using racemization free fragment conden-
sation strategy [58]. The Boc group was used for N-terminal pro-
tection and the C-terminus was protected as methyl ester.
Couplings were mediated by N-N0-dicyclohexylcarbodiimide/1-
hydroxybenzotriazole (DCC/HOBt) [58]. Deprotection of methyl es-
ter was carried out using saponification method and the Boc group
was deprotected by TFA (trifluoroacetic acid). The final product
was purified by column chromatograghy using silicagel (100–200
mesh) as stationary phase and chloroform methanol mixture as
the eluent. All the intermediates and purified final compound have
been fully characterised by various spectroscopic techniques like
NMR, IR and mass spectrometry. Single crystal suitable for X-ray
diffraction study of peptide I was obtained from water–ethanol
solution by slow evaporation.
Yield:
0.49 g
(90.0%).
;
Mp = 204–206 °C;
IR
(KBr):
3333,1666,1664 cmꢀ1
1H NMR 300 MHz (d6-DMSO, d ppm): 9.77
(m-ABA(4) NH, 1H, s); 8.55 (Leu(3) NH,1H, bs); 8.41 (m-ABA(4)
Ha, 1H, s), 8.00 (Aib(2) NH, 1H, s), 7.94(m-ABA(4) Hd, 1H, d,
J = 7.5 Hz), 7.60 (m-ABA(4) Hb, 1H, d, J = 7.2 Hz), 7.32 (m-ABA(4)
a
Hc, 1H, t, J = 7.8 Hz), 4.33–4.35 (C Hs of Ile(1) & Leu(3), 2H, m),
1.55–1.80 (CbHs of Ile(1) and Leu(3) 2H, m), 1.37–1.46 (CbHs of
c
Aib(2), 6H, s), 1.03–1.30 (C Hs of Ile(1) and Leu(3), 3H, m), 0.81–
c
0.85 (C Hs of Ile(1) and CdHs of Ile(1) & Leu(3), 12H, m); Anal.
Calcd. for C23H36N4O5 (448.54): C, 61.58; H, 8.09; N, 12.49%. Found:
C, 61.42; H, 7.92; N, 12.33%. HR–MS (M+Na+) = 471.29, Mcalcd
(M+Na)+ = 471.55.
2.1.1. Boc–Ile–Aib–Leu–m-ABA–OMe (1)
2.2. FT-IR spectroscopy
Boc–Ile–Aib–Leu–OH [52] (0.96 g, 2.23 mmol) was dissolved in
DMF (3 ml). m-ABA–OMe (0.61 g, 4.46 mmol) obtained from its
hydrochloride was added followed by DCC (0.69 g, 3.35 mmol)
and HOBt (0.36 g, 2.68 mmol). The reaction mixture was stirred
at room temperature for 5 days. The precipitated N-N0-dicyclohex-
ylurea (DCU) was filtered and diluted with ethyl acetate. The or-
ganic layer was washed with excess of water, 1 M HCl
(3 ꢁ 30 ml), 1 M Na2CO3 solution (3 ꢁ 30 ml) and again with water.
The solvent was then dried over anhydrous Na2SO4 and evaporated
in vacuo, giving a light yellow solid. Purification was done using sil-
ica gel as stationary phase and ethyl acetate–petroleum ether mix-
ture as the eluent.
IR spectra were examined using a Perkin Elmer – 782 model
spectrophotometer. The solid-state FT-IR measurements were per-
formed using the KBr disk technique.
2.3. NMR experiments
The 1H NMR study was recorded on a Bruker Avance 500 model
spectrometer operating at 300 MHz, respectively. The 2D experi-
ment was carried out in D2O on a Bruker DRX 500 MHz equipped
with a 5 mm broadband inverse probe head. The peptide concen-
tration was in the range 5–10 mM in D2O for 1H NMR and 20–
30 mM for 2D NMR measurements.
Yield: 1.11 g (94.0%). Mp = 110–111 °C; IR (KBr): 3306, 1723,
1665, 1528 cmꢀ1 1H NMR 300 MHz (CDCl3, d ppm): 9.17 (m-
;
ABA(4) NH, 1H, s); 8.52 (m-ABA(4) Ha, 1H, s); 8.15 (m-ABA(4)
Hd, 1H, d, J = 7.9 Hz); 7.71 (m-ABA(4) Hb, 1H, d, J = 7.7 Hz); 7.33
(m-ABA(4) Hc, 1H, t, J = 7.9 Hz); 7.24 (Leu(3) NH, 1H, d,
J = 7.8 Hz); 6.70 (Aib(2) NH, 1H, s); 5.21 (Ile(1) NH, 1H, d); 4.54
2.4. Circular dichroism spectroscopy
Aqueous solution of peptide I (1.5 mM) was used for obtaining
the CD spectrum. Far-UV CD measurements were recorded at 25 °C
with a 0.5 s averaging time, a scan speed of 50 nm/min, using a
JASCO spectropolarimeter (J 720 model) equipped with a 0.1 cm
pathlength cuvette. The measurements were taken at 0.2 nm
wavelength intervals, 2.0 nm spectral bandwidth and five sequen-
tial scans were recorded for the sample.
a
a
(C H of Leu(3), 1H, m); 3.86 (–OCH3, 3H, s); 3.80 (C H of Ile(1),
1H, m); 1.84–1.89 (CbHs of Ile(1) and Leu(3) 2H, m); 1.59 (CbHs
c
of Aib(2), 6H, s); 1.49 (Boc–CH3s, 9H, s); 1.23–1.30 (C Hs of
c
Ile(1), 3H, m); 0.92–0.93 (C Hs of Ile(1) and CdHs of Ile(1) &
Leu(3), 9H, m); 13C NMR 75 MHz (CDCl3, d ppm): 173.80, 171.84,
171.30, 167.09, 156.95, 139.09, 130.41, 128.53, 124.75, 124.52,
121.15, 81.28, 60.96, 57.02, 52.82, 51.92, 40.04, 36.49, 28.10,
27.40, 25.52, 25.11, 23.78, 23.25, 22.57, 20.76, 15.63, 11.51; Anal.
Calcd. for C29H46N4O7 (562.69): C, 61.89; H, 8.24; N, 9.95%. Found:
C, 61.75; H, 8.08; N, 9.80%.
2.5. Mass spectrometry
Mass spectra of peptide I was recorded on HEWLETT PACKARD
Series 1100MSD and Micromass Qtof Micro YA263 mass spectrom-
eters by positive mode electro spray ionization.
2.1.2. Boc–Ile–Aib–Leu–m-ABA–OH (2)
1 (1.0 g, 1.77 mmol) was dissolved in methanol (15 ml) and 2 M
NaOH (8 ml) was added. The reaction mixture was stirred at room
temperature for 2 days. The progress of the reaction was monitered
by TLC. After completion of the reaction the methanol was
2.6. Crystal data for peptide I
C46H90N8O14.5, M = 987.19, monoclinic, spacegroup C2, Z = 4,
a = 30.820(3) Å, b = 8.603(1) Å, c = 20.994(5) Å, b = 109.41(2)°,